Standard treatment of primary central nervous system lymphoma (PCNSL) in countries with limited resources remains conventional chemotherapy, with or without whole brain radiotherapy (WBRT). To evaluate the treatment outcomes, prognostic factors and costs in patients with PCNSL treated with high-dose Methotrexate, vincristine and procarbazine, plus Rituximab (MVP-R) followed by consolidation with reduced dose (rd) WBRT and Cytarabine chemotherapy. We conducted an institutional audit of the first line treatment of patients with PCNSL, who were treated with MVP-R regimen, WBRT, or both between September 2011 and January 2020. Long term neuro-cognitive toxicity was recorded on follow up. The 5-year overall survival (OS) was the primary end point. Of 54 patients, 42 were evaluable [median age: 54 years (19–73 years)]. The commonest subtype was activated B-cell subtype (90%). At presentation, multiple and deep brain lesions were reported in 38 and 73% patients, respectively. Combined chemoimmunotherapy was given to 41 patients and WBRT to 29 patients. 27 patients (65%) achieved a complete response, and 22 received rdWBRT. 7 patients with partial response received conventional dose WBRT. Among tested prognostic factors, response to treatment was the single most significant determinant. At a median follow-up of 58 months, the 5-year progression free survival was 42%, and 5-year OS was 60%. The median direct hospital costs incurred by most patients for investigations and treatment were $1976.45 and $12,078.49, respectively. MVP-R is a well-tolerated regimen with substantial long term outcomes. Among all prognostic factors, response to therapy is the most significant.

在资源有限的国家，原发性中枢神经系统淋巴瘤 (PCNSL) 的标准治疗仍然是常规化疗，联合或不联合全脑放疗 (WBRT)。评估 PCNSL 患者接受高剂量甲氨蝶呤、长春新碱和丙卡巴肼加利妥昔单抗 (MVP-R) 治疗后的治疗结果、预后因素和费用，然后进行减量巩固治疗（rd) WBRT 和阿糖胞苷化疗。我们对 PCNSL 患者的一线治疗进行了机构审核，这些患者在 2011 年 9 月至 2020 年 1 月期间接受了 MVP-R 方案、WBRT 或两者均接受治疗。在随访中记录了长期神经认知毒性。5 年总生存期 (OS) 是主要终点。54 名患者中，42 名可评估 [中位年龄：54 岁（19-73 岁）]。最常见的亚型是活化的 B 细胞亚型 (90%)。就诊时，分别有 38% 和 73% 的患者报告了多发性和深部脑损伤。41 名患者接受了联合化学免疫治疗，29 名患者接受了 WBRT。27 名患者 (65%) 获得完全缓解，22 名患者接受rdWBRT。7 名部分反应的患者接受了常规剂量的 WBRT。在测试的预后因素中，对治疗的反应是最重要的决定因素。中位随访 58 个月时，5 年无进展生存率为 42%，5 年 OS 为 60%。大多数患者因调查和治疗而产生的直接住院费用中位数分别为 1976.45 美元和 12,078.49 美元。MVP-R 是一种耐受性良好的方案，具有显着的长期结果。在所有预后因素中，对治疗的反应最为重要。